GPN Vaccines

GPN Vaccines

Creating a comprehensive vaccine targeting Streptococcus pneumoniae, the leading bacterial pathogen worldwide.

Launch date
Employees
Market cap
-
Enterprise valuation
€176m (Public information from Jun 2024)
Company register number 621789008
Adelaide South Australia (HQ)
  • Edit
DateInvestorsAmountRound
-

N/A

-
*

AUD7.0m

Series A

AUD1.0m

Grant
*

N/A

Series A
*

AUD9.0m

Series A
*

AUD18.0m

Valuation: AUD300m

Series B
Total Funding€22.3m

Recent News about GPN Vaccines

Edit